Estradiol valerate and dienogest:A new approach to oral contraception

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Most combination oral contraceptives contain ethinyl estradiol and a progestin. A new and novel oral contraceptive formulation combines estradiol valerate (E2V) with dienogest (DNG) in a four-phase dosing regimen. 17β-estradiol is a naturally-occurring estrogen, and a contraceptive pill containing such an estrogen offers potential benefts with regard to metabolic side effects and adverse events. Dienogest is derived from 19-nortestosterone and exerts profound progestational effects on the endometrium, but it differs from other progestins in its class by its antiandrogenic activity. Estradiol valerate plus dienogest (E2V/DNG) is now available in a four-phasic regimen that integrates an estrogen stepdown and progestin stepup dosing approach along with a short two-day hormone-free interval. This regimen offers safe, reliable contraception and has been shown to be an effective treatment for heavy menstrual bleeding. Metabolic effects and adverse events appear similar to those reported with oral contraceptives containing ethinyl estradiol.

Original languageEnglish (US)
Pages (from-to)281-286
Number of pages6
JournalInternational Journal of Women's Health
Issue number1
StatePublished - 2011


  • Combination
  • Dienogest
  • Estradiol valerate
  • Oral contraception

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology
  • Maternity and Midwifery


Dive into the research topics of 'Estradiol valerate and dienogest:A new approach to oral contraception'. Together they form a unique fingerprint.

Cite this